BEIGF:OTCMKTS
BeOne Medicines
US$21,95
0,00%
(0,00) 1 HR
9 Jun, 12.49.46 GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk BEIGF...
Kapitalisasi pasar
44,66 M
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
US$24,92
Harga rendah dalam 52 minggu terakhir
US$21,95
Beta
0,84
Saham beredar
1,43 M
Jumlah karyawan
12 rb
Kapitalisasi pasar
44,66 M
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
US$24,92
Harga rendah dalam 52 minggu terakhir
US$21,95
Beta
0,84
Saham beredar
1,43 M
Jumlah karyawan
12 rb
Artikel berita
Dari sumber web dan partner berita
TipRanks
·
25 menit yang lalu
BeOne Medicines Advances BGB-43395 With New Drug Interaction Study Update
MarketBeat
·
49 menit yang lalu
BeOne Medicines (NASDAQ:ONC) Stock Falls 5.8% - Here's What Happened
AD HOC NEWS
·
1 hari yang lalu
BeOne Medicines stock gained 1.00 percent on October 5 as targets rose
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tentang BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Karyawan12 rb
Didirikan28 Okt 2010
Kantor Pusat-
Sektor-
Situsbeonemedicines.com